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 Clinical Utility of Vitamin D in the Treatment of Idiopathic Chronic 
Lymphopenia: A Possible Intervention 
 
Abstract: Aim: To open the possibility of using vitamin D in cases of idiopathic 
lymphopenia. Background: In addition to its participation in the homeostasis of 
calcium and phosphorus, vitamin D has immunomodulatory mechanisms, so, its 
deficiency, apart from being associated with bone abnormalities, accompanies the 
development of certain autoimmune diseases. Case Description: It is a case of 
leukopenia associated with idiopathic lymphopenia of four years of evolution, in a 
51-year-old woman, with history of hemithyroidectomy and osteopenia in the 
lumbar spine. Management initially consisted in supplementation with calcium 
and ibandronic acid. However, in the presence of hypercalciuria, vitamin D 
deficiency was suspected, so its serum levels were quantified, confirming the 
deficiency, then calcitriol was added to the treatment. Five months after the first 
dose of calcitriol, the leukocytes and lymphocytes levels were within normal 
range. Conclusion: There are many therapeutic schemes to treat vitamin D 
deficiency, however, nowadays no cases have been reported confirming the 
positive effect on lymphocytes count after vitamin D supplementation. Clinical 
significance: Until now, cases of idiopathic lymphopenia have not been given any 
specific therapeutic alternative, and vitamin D could have a positive effect if there 
is an autoimmune component, and perhaps even offer a greater spectrum of 
benefits. 
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BACKGROUND 
Vitamin D is involved in diverse processes other than calcium 
regulation, such as: antineoplastic actions, glucose metabolism, muscular 
activity and immune system regulation (Gómez de Tejada, M. J., 2014). 
Vitamin D deficiency is a high-prevalent condition worldwide due to 
alimentary, geographic and socioeconomic factors. As a matter of fact, 
this deficiency generates anomalies in the regulation of calcium, 
phosphorus and bone homeostasis. 
 
It has been documented that a viable therapy to correct vitamin D deficiency and keep adequate serum levels is to 
administer vitamin D2 or D3 at a dose of 50,000 IU once a week for 2 months, following an adjustment in the 
maintaining dose to 50,000 IU at 2-4 weeks intervals. Since the availability of these capsules is insufficient, other 
alternative schemes which have demonstrated efficiency have been prescribed (Holick, M. F., 2007). Moreover, the 
Endocrine Society’s Practice Guidelines Committee recommends that for optimal musculoskeletal health, serum vitamin 
D levels must be at least 30 ng/ml (Holick, M. F., 2017). 
 
Additionally, both the Spanish Agency for Medicines and Sanitary Products (AEMPS), and the United States Food 
and Drug Administration (FDA), indicate calcitriol use of in all those pathologies in which the synthesis capacity of this 
compound is abolished, such as: chronic renal insufficiency, idiopathic hypoparathyroidism, postsurgical 
hypoparathyroidism, pseudohypoparathyroidism, renal osteodystrophy, vitamin D-dependent rickets, vitamin D-resistant 
hypophosphatemic rickets and osteomalacia [Ficha técnica rocaltrol, 2021 & Calcitriol. 2021]. In fact, calcitriol therapy 
has demonstrated a greater increase in the bone mineral density in short and long term, and a decrease in fractures 
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On the other hand, the idiopathic lymphopenia 
diagnosis is established when the criteria given by the 
Center for Disease Control and Prevention (CDC) are 
met: 1) CD4 lymphocytes cellular depletion (absolute 
values <300 cells/mL or <20% of total lymphocytes in 
two different measures at least 6 weeks apart), 2) 
Absence of HIV serologic evidence, 3) Lack of any 
immunodeficiency or therapy associated with CD4 
lymphocytes levels depletion. It is worth noting that 
there is an association between vitamin D deficiency 
with a decrease in the lymphocytes-leukocytes counts in 
the setting of infectious diseases (COVID-19 and HIV-
AIDS) and autoimmune diseases, such as Type 1 
Diabetes Mellitus (T1DM), Systemic Lupus 
Erythematosus (SLE) and rheumatoid arthritis; 
nevertheless, vitamin D deficiency has not been related 




It is a case of a 51-year-old female patient, who 
since 2017 had leukopenia with initial values of 3,900 
leukocytes/µL, associated with lymphopenia of 1,176 
lymphocytes/µL, without any attributable cause. 
According to the important pathological personal 
antecedents, it stands out a hemithyroidectomy 
performed in 2014 due to a micro-macro follicular 
adenoma, as a consequence, she developed primary 
hypothyroidism, currently treated with levothyroxine. 
In 2017, she manifested osteoarticular discomfort, thus 
a densitometry was performed, identifying osteopenia at 
the lumbar spine level, initiating treatment with 
ibandronic acid and supplemental calcium. After 
confirming hipercalciuria in 2020, treatment was 
changed to alendronate and cholecalciferol. Throughout 
her periodic evaluations, bilateral renal lithiasis, 
segment V hepatic hemangioma, intramural and small 
element uterine myomatosis, colonic diverticulosis and 
persistent leukopenia associated with lymphopenia were 
recorded. 
 
In august 2020, urinary calcium of 72 mg/day (100-
300 mg/day) was determined; suspecting vitamin D 
deficiency, its serum value was quantified, obtaining 
17.6 ng/ml of 25(OH) D (20-100 ng/ml) and it was 
decided to incorporate calcitriol to the initial treatment. 
Five months after this first dose, the leukocytes and 
lymphocytes values increased and reached the normal 
range (Figure 1). 
 
 
Figure 1: Leukocyte and Lymphocyte Levels Variations. One Month After Blood Count In July 2020, Treatment With 
Calcitriol Was Started. 
 
DISCUSSION 
Based on available information, it is recommended 
that patients at risk of vitamin D deficiency or those 
who have a greater susceptibility to infections such as 
influenza and COVID-19, should be prescribed with 
vitamin D as a preventive dose (Romo, A., et al., 2020). 
A study carried out in COVID-19 patients who required 
hospitalization, determined that, on average, their 
vitamin D levels were deficient (16.54 ± 7.37) and only 
4.1% maintained optimal levels. Among the featured 
data, it was noticeable that none of the patients with 
adequate levels of this vitamin died and that the higher 
mortality rate was presented in the patients with 
deficient levels, despite the fact no significant statistical 
association was found between the different categories 
of vitamin D and mortality; nonetheless, it was reported 
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that patients with vitamin D levels below 8 ng/mL had 
3.69 times higher risk to die (Reyes, R. A., et al., 2020). 
 
Vitamin D intoxication is an uncommon event, 
which can be caused by an excessively high ingestion, 
doses higher than >50 000 IU/day dose, elevate the 
values of 25(OH)D over 150 ng/ml and are related to 
hypercalcemia and hyperphosphatemia. Similarly, a 
dose of 10 000 IU/day of vitamin D3 for up to 5 months 
maximum does not carry toxicity risk (Holick, M. F., 
2007). 
 
The vitamin D endogenous production occurs by 
photochemical conversion of 7-dehydrocholesterol to 
cholecalciferol in the epidermis when exposed to UV-B 
rays, later it is hydrolyzed in the liver and is converted 
in 25-hydroxyvitamin D (25(OH)D), finally, in the 
kidney, this compound is converted into 1,25 
dihydroxyvitamin D (1,25(OH)2D3), the active form of 
this hormone (Valero, M. et al., 2007; & Zuluaga, N. et 
al., 2011). It has been demonstrated that the vitamin D 
receptor (VDR) and the vitamin D activating enzyme, 
1-alpha-hydroxylase (CYPB27B1), are expressed in 
different organs of the human body such as: bone, 
intestine, kidney, pancreas, prostate and even immune 
system cells (Sassi, F., et al., 2018). 
 
Aside from its main role in calcium homeostasis and 
skeletal system regulation, in recent decades the 
immunomodulatory mechanisms that vitamin D exerts 
on the immune system have been clarified. Regarding 
innate immunity, 1,25(OH)2D3 improves the ꞵ2-
defensin and the antimicrobial cathelicidin peptide 
(CAMP) production by keratinocytes, macrophages, 
monocytes and neutrophiles. It also stimulates 
chemotaxis and phagocytosis mechanisms, likewise, it 
improves macrophages differentiation and maturation 
(Sassi, F., et al., 2018; & Skrobot, A., et al., 2018). 
Regarding adaptive immunity, it reduces antigen 
presentation, activation of effector T lymphocytes (Th1, 
Th17) and secretion of proinflammatory cytokines such 
as IL-17, TNFα, IL-22 e IFN-ɣ; simultaneously, it 
induces Th2 and T regulatory cells activation, both 
involved in the proinflammatory reactions reduction. 
Moreover, 1,25(OH)2D3 inhibits the post-change and 
plasma B cells production, thus causing a decrease in 
the immunoglobulins secretion (Skrobot, A., et al., 
2018; & Höck A. D., 2014). (Figure 2). 
 
 
Figure 2: Vitamin D actions. 1, 25 dihydroxyvitamin D roll in adaptive immunity produces different effects over the 
variety of lymphocytes, for instance, it influences lymphocytes B to downregulate the activation and production of 
immunoglobulin as well as reducing Th1 and Th17 activation of cytokines Interleukin 17, Interleukin 22, Interferon 
gamma, and Tumor Necrosis Factor; on the contrary it increases the activation of Th2 and regulatory T cells. On the 
other hand, 1,25 dihydroxyvitamin D acts on the innate immunity by increasing the cyclic adenosine monophosphate and 
the production of beta-defensin-2. 
 
An inflammatory response with high concentrations 
of pro-inflammatory cytokines has been observed in 
patients with severe forms of COVID-19 who present 
lymphopenia, especially in cases of T lymphocytes and 
vitamin D deficiency, conditions associated with the 
development of multiple organ failure, responsible for 
death in a significant proportion of these patients 
(Romo, A. et al., 2020). 
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There are several autoimmune diseases associated 
with vitamin D deficiency, such as T1DM, SLE and 
Hashimoto's thyroiditis; in which, a therapeutic benefit 
has been evidenced with the use of vitamin D 
supplements. The vitamin D immunomodulatory effects 
include pancreatic-cells apoptosis prevention, leading to 
insulin secretion improved function in T1DM; fatigue 
symptoms and disease activity reduction, and adaptive 
immunity activation enhancement in SLE; as well as the 
reduction in anti-thyroid peroxidase (TPOAb) and anti-
thyroglobulin (TgAb) antibodies levels in Hashimoto's 
thyroiditis ( Bellan, M., et al., 2020). 
 
Another pathology in which vitamin D deficiency 
has been extensively documented is Multiple Sclerosis 
(MS), especially during recurrent episodes; through the 
analysis of various cohort studies in large population 
groups, it has been suggested the use of vitamin D 
supplementation to reduce the risk of appearance and 
development of this disease (Munger, K. L., et al., 
2004; VanAmerongen, B. M., et al., 2004; & Ascherio, 
A., et al., 2010). 
 
In the present case, within the approach of the 
patient with vitamin D, its possible effect for the 
treatment of idiopathic lymphopenia is analyzed. 
Vitamin D insufficiency corresponds to values of 21-29 
ng/ml of 25 (OH) D and has a high prevalence 
worldwide, affecting approximately 50% of the 
population and 67.1% of women with osteoporosis in 
Mexico. On the other hand, vitamin D deficiency is 
considered when serum 25 (OH) D values are <20 
ng/ml (Holick, M. F., 2007; & Lips, P. et al., 2006). 
 
In our patient, it was ruled out that the decrease in 
the leukocyte-lymphocyte cellular counts was caused by 
malignant etiologies, in the same way, complementary 
studies were carried out in search of autoimmune 
diseases, HIV infection and other attributable causes, 
without positive results. According to the criteria 
established by the CDC, it was classified as idiopathic 
lymphopenia, for which treatment with calcitriol was 
started. Vitamin D supplementation improved the 
patient's clinical setting regarding musculoskeletal 
discomfort; likewise, in the hematic biometry 
performed five months after starting the treatment, an 
increase in the number of leukocytes and lymphocytes 
was found, reaching the normal range. 
 
A limitation of this case report is the lack of 
determination of lymphocyte subpopulations, however 
the elevation of the total leukocyte and lymphocyte 
counts, allow us to infer a favorable effect of vitamin D. 
It is mandatory to perform controlled studies with a 
larger sample size to determine vitamin D deficiency in 
patients with autoimmune diseases; as well as 
identifying the levels of vitamin D in patients with 
idiopathic lymphopenia, and to make a close record of 




According to the reviewed literature, taking into 
account the vitamin D immunomodulatory functions, 
and considering the evidence in favor of 
supplementation in pathologies that are deficient in this 
vitamin and the findings obtained in the present case, it 
is suggested that Vitamin D supplementation as a 
treatment in patients with idiopathic lymphopenia and 
autoimmune diseases, should be considered in the 
comprehensive management of these patients, due to its 
effect associated with increased serum levels of 
lymphocytes, improving the symptoms and clinical 
course of the disease. 
 
Clinical Significance 
Until now, cases of idiopathic lymphopenia have not 
been given any specific therapeutic alternative, and 
vitamin D could have a positive effect if there is an 
autoimmune component, and perhaps even offer a 
greater spectrum of benefits. 
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